Precision BioSciences (Precision BioSciences) Cash-to-Debt : 3.73 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Precision BioSciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.73.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Precision BioSciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Precision BioSciences's Cash-to-Debt or its related term are showing as below:

DTIL' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.73 Med: 15.77 Max: No Debt
Current: 3.73

During the past 7 years, Precision BioSciences's highest Cash to Debt Ratio was No Debt. The lowest was 3.73. And the median was 15.77.

DTIL's Cash-to-Debt is ranked worse than
58.83% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs DTIL: 3.73

Precision BioSciences Cash-to-Debt Historical Data

The historical data trend for Precision BioSciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Precision BioSciences Cash-to-Debt Chart

Precision BioSciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

8.54

15.77

7.60

3.73

Precision BioSciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															7.60	5.95	4.92	5.12	3.73

Competitive Comparison of Precision BioSciences's Cash-to-Debt

For the Biotechnology subindustry, Precision BioSciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Precision BioSciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Cash-to-Debt falls into.

Precision BioSciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Precision BioSciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	116.678	/	(23.545	+	7.723)
	=	3.73

Precision BioSciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	116.678	/	(23.545	+	7.723)
	=	3.73

Precision BioSciences (NAS:DTIL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Precision BioSciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Precision BioSciences (Precision BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PBS:Germany

Address

302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701

Website

https://www.precisionbiosciences.com

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Executives

J. Jefferson Smith	10 percent owner	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Alan List	officer: Chief Medical Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Michael Amoroso	director, officer: President and CEO	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Dario Scimeca	officer: General Counsel	C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly	officer: Interim CFO	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Pharma Ag Novartis	10 percent owner	LICHTSTRASSE 35, CH-4002, BASEL V8
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056
Derek Jantz	director, 10 percent owner, officer: Chief Scientific Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Melinda Brown	director	10 HUDSON YARDS, NEW YORK NY 10001
Shari Lisa Pire	director	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson	officer: Chief Development Officer	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Stanley Frankel	director	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Matthew R. Kane	director, 10 percent owner, officer: President and CEO	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shane Barton	officer: VP & Corporate Controller	C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701